Home » Antisoma’s AS1413 Gains FDA Fast Track Status for Myeloid Leukemia
Antisoma’s AS1413 Gains FDA Fast Track Status for Myeloid Leukemia
Cancer drug developer Antisoma Thursday announced that the FDA has granted Fast Track designation to the Company’s novel DNA intercalator, AS1413 (amonafide L-malate), for the treatment of secondary acute myeloid leukemia.
MarketWatch
MarketWatch
Upcoming Events
-
07May
-
14May
-
23May
-
30May
-
21Oct